Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of rozanolixizumab in pediatric generalized myasthenia gravis
jRCT2031250120Active, not recruiting
- Sponsor
- UCB
- Start
- Oct 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Open-label, single-arm trial of rozanolixizumab in myasthenia gravis (MG), sponsored by UCB. Primary endpoints: Occurrence of serious treatment-emergent adverse events, Occurrence of treatment-emergent adverse events leading to permanent withdrawal of investigational medicinal product and 1 more. Started Oct 2025; status: active, not recruiting.
02
Drugs
rozanolixizumab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on jRCT2031250120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250120.